Returns
NAV and returns as at 20 Aug 2026
Lumpsum · point to point
1W
-0.39%
1M
+1.86%
3M
+9.53%
6M
+21.72%
YTD
+20.15%
1Y
+16.36%
2Y CAGR
+13.2%
3Y CAGR
+24.04%
5Y CAGR
+16.79%
10Y CAGR
+14.93%
SIP · XIRR on monthly instalments
6M SIP
+56.69%
1Y SIP
+31.83%
2Y SIP
+19.02%
3Y SIP
+21.12%
5Y SIP
+22.23%
10Y SIP
+19.74%
Full history SIP
+19.74%
Periods up to one year are absolute; longer periods are annualised (CAGR). SIP figures are the XIRR of a fixed monthly instalment over the same window. — means this scheme’s NAV history does not cover that period — across all 1648 schemes, 68% have a 3-year figure, 48.8% a 5-year one, and 32.7% a 10-year one.
Top holdings
as at 31 Jul 2026 · source: AMC monthly portfolio disclosure
EQ - SUN PHARMACEUTICALS INDUSTRIESPharmaceuticals & Biotechnology
8.71%
EQ - DIVIS LABORATORIES LTD.Pharmaceuticals & Biotechnology
5.57%
EQ - AJANTA PHARMA LTD.Pharmaceuticals & Biotechnology
4.8%
EQ - CAPLIN POINT LABORATORIES LTDPharmaceuticals & Biotechnology
3.95%
EQ - LUPIN LTD.Pharmaceuticals & Biotechnology
3.59%
EQ - GLAND PHARMA LTD.Pharmaceuticals & Biotechnology
3.56%
EQ - APOLLO HOSPITALS ENTERPRISE LTHealthcare Services
3.46%
EQ - DR REDDYS LABORATORIES LTD.Pharmaceuticals & Biotechnology
3.1%
EQ - ALKEM LABORATORIES LTDPharmaceuticals & Biotechnology
3.1%
EQ- GLOBAL HEALTH LTD.Healthcare Services
2.81%
Top 10 42.65%Securities 44Securities total 97.06%Cash & equivalents 2.92%
The ten largest securities by weight, out of 44 disclosed. Weight is percent of net assets as filed. Cash-equivalent lines (TREPS, reverse repo, net receivables, margin) and derivative legs are counted in the chips above but not ranked among securities, because a short futures leg is filed as a negative weight and sorting it alongside a shareholding describes no portfolio. A portfolio is a point-in-time filing and changes every month.
Risk
Volatility · annualised · 3Y
14.76%
Volatility is the annualised standard deviation of daily NAV moves over the last three years; max drawdown is the deepest peak-to-trough fall in that same window. Where a scheme has less than three years of NAV, the window is what it actually has and is labelled as such — never as three years. Sharpe is as disclosed in the scheme key-ratio feed (as at 24 July 2026).
Beta and alpha are not shown. No benchmark series in the source.
Cost
Expense ratio1.28%
Category average1.73%
Exit load1%
52W high / low₹390.8277 / ₹304.4841
Expense ratio 1.28% vs a category average of 1.73% — 0.45 percentage points lower. Among Sectoral/ Thematic schemes disclosing an expense ratio it is 110th of 166, cheapest first.
Expense ratio and category average are as disclosed against this scheme in the source; 78.5% of schemes here carry one. The ratio is charged inside the NAV, so every return on this page is already net of it.
Scheme facts
SEBI sub-category
Sectoral/ Thematic
Plan / option
Direct Growth
Benchmark
BSE Health Care - TRI
Fund manager
Kamal Gada
Launched
27 May 1999
NAV history here
10.0y
ISIN
INF789F01TO9
AMFI scheme code
120782
SEBI riskometer
Very High
Exit load
1%
Lock-in
None
Minimum lumpsum
₹5,000
Exit load, as disclosed: 1% on or before 30D · Nil after 30D
Not shown on this page, and why
Star rating — GFS is an AMFI-registered distributor (ARN-169480), not a SEBI-registered investment adviser. It does not rate schemes.
Scheme AUM — Scheme-level AUM is not in the source; only AMC-total AUM, which is a different number.
Minimum SIP — Not present in the source.
Beta and alpha — No benchmark series in the source.